Phaseline

Targets › TRPC6

TRPC6 (Short transient receptor potential channel 6): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Immunology; next expected readout Feb 2027.

Non-selective, calcium-permeable cation channel. Mediates calcium entry following G(q)-coupled receptor or receptor tyrosine kinase activation, which triggers phospholipase C (PLC)-mediated hydrolysis of phosphatidylinositides and production of diacylglycerol (DAG) that directly activates TRPC6. (UniProt, Q9Y210)

Open in Phaseline: the race on TRPC6, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Applied BiologyHyperforin
TRPC channel activator and plant extract with anti-inflammatory properties
TRPC6Phase 1Chemotherapy Induced AlopeciaFeb 2027

Conditions

Chemotherapy Induced Alopecia (1)

Modalities

small molecule (1)

Companies

Applied Biology (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.